Glenmark launches Teneligliptin + Dapagliflozin Fixed-Dose Combination for adults with Type 2 diabetes

The company aims to improve glycemic control in adult patients with uncontrolled type‐2 diabetes

Glenmark Pharmaceuticals became the first to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination (FDC) for the treatment of adult patients with type 2 diabetes, especially the ones with comorbidities. Marketed under the brand name Zita D; it contains Teneligliptin (20mg) + Dapagliflozin (5 mg/10 mg), and must be taken once daily under prescription to improve glycemic control & prevent complications in adult patients with type 2 diabetes, especially the ones with comorbidities.

Alok Malik, EVP & Business Head ‐ India Formulations, Glenmark Pharmaceuticals, said, “Diabetes is growing in India at an alarming rate, and eight out of every ten diabetic patients suffer from comorbidities. Glenmark being a leader in the diabetes segment in India is proud to bring Zita D, a well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities.”